KDR and neoplasm: It is worth noting that VEGFR2 knocking out CD8+ T cells can down-regulate TOX expression and reactivate tumor-specific CD8+ T cells, confirming that targeting the VEGF/VEGFR2 pathway can reverse T cell depletion and enhance the antitumor effect of ICIs.